dc.contributor.author | P. Lutzky, Viviana | |
dc.contributor.author | Corban, Monika | |
dc.contributor.author | Heslop, Lea | |
dc.contributor.author | E. Morrison, Leanne | |
dc.contributor.author | Crooks, Pauline | |
dc.contributor.author | F. Hall, David | |
dc.contributor.author | Coman, William | |
dc.contributor.author | A. Thomson, Scott | |
dc.contributor.author | J. Moss, Denis | |
dc.contributor.editor | Lynn W Enquist | |
dc.date.accessioned | 2017-05-03T15:55:31Z | |
dc.date.available | 2017-05-03T15:55:31Z | |
dc.date.issued | 2010 | |
dc.date.modified | 2010-11-12T08:34:13Z | |
dc.identifier.issn | 0022538X | |
dc.identifier.doi | 10.1128/JVI.01303-09 | |
dc.identifier.uri | http://hdl.handle.net/10072/34983 | |
dc.description.abstract | Epstein-Barr virus (EBV) is associated with several malignant diseases including nasopharyngeal carcinoma (NPC), a common neoplasm throughout southeast Asia. Radiotherapy and chemotherapy can achieve remission, but a reemergence of disease is not uncommon. Therefore, there is a need for specific therapies that target the tumor through the recognition of EBV antigens. In NPC, latent membrane protein 1 (LMP1) and LMP2 offer the best opportunity for specific targeting since they are typically expressed and T-cell determinants in each of these proteins have been defined. We have attempted to maximize the opportunity of incorporating every possible CD4 and CD8 determinant in a single formulation. We have achieved this by generating a scrambled protein incorporating random overlapping peptide sets from EBNA1, LMP1, and LMP2, which was then inserted into a replication-deficient strain of adenovirus (adenovirus scrambled antigen vaccine [Ad-SAVINE]). This report describes the construction of this Ad-SAVINE construct, its utility in generating LMP1 and LMP2 responses in healthy individuals as well as NPC patients, and its capacity to define new epitopes. This formulation could have a role in NPC immunotherapy for all ethnic groups since it has the potential to activate all possible CD4 and CD8 responses within EBNA1 and LMPs. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | American Society for Microbiology | |
dc.publisher.place | United States | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 407 | |
dc.relation.ispartofpageto | 417 | |
dc.relation.ispartofissue | 1 | |
dc.relation.ispartofjournal | Journal of Virology | |
dc.relation.ispartofvolume | 84 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Clinical Pharmacology and Therapeutics | |
dc.subject.fieldofresearch | Biological Sciences | |
dc.subject.fieldofresearch | Agricultural and Veterinary Sciences | |
dc.subject.fieldofresearch | Medical and Health Sciences | |
dc.subject.fieldofresearchcode | 111502 | |
dc.subject.fieldofresearchcode | 06 | |
dc.subject.fieldofresearchcode | 07 | |
dc.subject.fieldofresearchcode | 11 | |
dc.title | Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2010 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Coman, William B. | |